ClinicalTrials.gg
RecruitingNCT07431281Updated Oct 16, 2026

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Phase 3 interventional study of Sonesitatug vedotin and Rilvegostomig in Gastric Cancer, Gastroesophageal Junction Adenocarcinoma and Esophageal Cancer, sponsored by AstraZeneca. Recruiting at 314 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 16, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.

Planned enrollment
Largest of 27
2,130 · median 124
Started
2026
with 2 others
Phase 3
4 of 30
2 open now
Primary completion
2029-08
later than 15 of 17 live
Registered
28th of 30
by date

Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one has the largest planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 15 of the 17 other live ones, and was the 28th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Stomach Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Read the detailed description

The purpose of this Phase III study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in 1L CLDN18.2-positive, HER2-negative gastric, GEJ, and esophageal adenocarcinoma, and the clinical performance of the investigation in vitro diagnostics (IVDs). The study will include 2 cohorts to provide a treatment option for all participants that are HER2-negative and CLDN18.2-positive. Cohort 1 will evaluate sonesitatug vedotin in combination with rilvegostomig with capecitabine in participants who are CLDN18.2-positive and programmed death-ligand 1 (PD-L1) positive. Cohort 2 will evaluate sonesitatug vedotin in combination with capecitabine in participants who are CLDN18.2-positive and PD-L1 negative or immune checkpoint inhibitor (ICI) ineligible.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Esophageal Cancer

Keywords

  • Advanced Gastroesophageal Junction (GEJ) Adenocarcinoma,
  • Advanced Gastric Adenocarcinoma,
  • Advanced Esophageal Adenocarcinoma,
  • Metastatic Gastric Adenocarcinoma,
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma,
  • Metastatic Esophageal Adenocarcinoma,
  • Claudin 18.2,
  • PD-L1,
  • Human epidermal growth factor receptor 2 (HER2) Negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • Participant must be 18 years or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
  • Previously untreated documented unresectable, locally advanced, or gastric, GEJ, or distal esophagus (distal third of the esophagus) adenocarcinoma
  • Positive CLDN18.2 expression, as determined prospectively by central IHC testing
  • Confirmed CPS status by central IHC testing and ICI eligibility per investigator judgement is required to determine cohort eligibility as described below:

    1. Cohort 1: PD-L1 positive as determined by central IHC testing and the participant is deemed ICI eligible per investigator judgement.
    2. Cohort 2: PD-L1 negative as determined by central IHC testing OR the participant is ICI ineligible
  • performance status of 0 or 1 with no deterioration to > 1 over the previous 2 weeks prior to baseline at screening and prior to randomisation.
  • Minimum of ≥ 12 weeks.
  • At least one lesion (measurable and/or non-measurable) that can be accurately assessed by the investigator based on 1.1.
  • Adequate organ and bone marrow function as specified in the protocol
  • Body weight ≥ 35 kg.
  • Sex and requirements

Exclusion criteria

Exclusion Criteria:

  • Known -positive status
  • Significant or unstable gastric bleeding and/or untreated gastric ulcers.
  • Active or history of or inflammatory disorders requiring systemic treatment with or other treatment or assessed by investigator as not appropriate to participate due to undue risk are excluded.
  • CNS pathology
  • pleural effusions or ascites and/or pleural effusions or ascites that require drainage, peritoneal shunt, or indwelling catheter/drain.
  • Require parenteral nutrition support due to gastric or gastrointestinal obstruction.
  • Peripheral neuropathy, sensory or motor, ≥ Grade 2 at screening.
  • Persistent toxicities caused by previous anticancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
  • Cardiac abnormalities as outlined in the protocol
  • Uncontrolled diabetes or diabetic neuropathy within 3 months prior to randomisation.
  • Infectious disease including active hepatitis A infection; uncontrolled and/or chronic or active hepatitis B with HBV DNA ≥ 100 IU/mL; Known chronic, active, or uncontrolled ; infection that is not well controlled
  • Known partial or total DPD enzyme deficiency
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,130 participants (estimated)

Study arms

  • Experimental
    Arm A

    Sonesitatug vedotin + Rilvegostomig + Capecitabine

    Drug: Sonesitatug vedotin · Drug: Rilvegostomig · Drug: Capecitabine

  • Experimental
    Arm B

    Sonesitatug vedotin + Nivolumab + Capecitabine

    Drug: Sonesitatug vedotin · Drug: Nivolumab · Drug: Capecitabine

  • Active comparator
    Arm C

    Nivolumab + CAPOX OR Nivolumab + FOLFOX * nivolumab, capecitabine, oxaliplatin * nivolumab, 5-Fluorouracil, leucovorin, oxaliplatin

    Drug: Nivolumab · Drug: Capecitabine · Drug: 5-Fluorouracil · Drug: Oxaliplatin · Drug: Leucovorin

  • Experimental
    Arm D

    Sonesitatug vedotin + Capecitabine

    Drug: Sonesitatug vedotin · Drug: Capecitabine

  • Active comparator
    Arm E

    Zolbetuximab + CAPOX or Zolbetuximab + FOLFOX: * zolbetuximab, capecitabine, oxaliplatin * zolbetuximab, 5-Fluorouracil, leucovorin, oxaliplatin CAPOX or FOLFOX: * oxaliplatin, capecitabine, * 5-Fluorouracil, leucovorin, oxaliplatin

    Drug: Capecitabine · Drug: 5-Fluorouracil · Drug: Oxaliplatin · Drug: Zolbetuximab · Drug: Leucovorin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) (Cohort 1 and Cohort 2)

    PFS is defined as time from randomisation until progression per RECIST 1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 5 years

  2. Overall Survival (OS) (Cohort 1)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Overall Survival (OS) (Cohort 2)

    OS is defined as the time from randomisation until the date of death due to any cause.

    Time frame: Up to approximately 5 years

  2. Overall Survival (OS) (Cohort 1)

    OS is defined as time from randomisation until date of death due to any cause. Arm B versus C.

    Time frame: Up to approximately 5 years

  3. Progression Free Survival (PFS) (Cohort 1)

    PFS is defined as time from randomisation until progression per RECIST 1.1 or death due to any cause, whichever occurs first. Arms B versus C.

    Time frame: Up to approximately 5 years

  4. Objective Response Rate (ORR) (Cohort 1 and Cohort 2)

    ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, per RECIST 1.1.

    Time frame: Up to approximately 5 years

  5. Duration of Response (DoR) (Cohort 1 and Cohort 2)

    DoR (per RECIST 1.1) is derived for confirmed objective responses (CR or PR) only and is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression (ie, date of PFS event - date of first response + 1).

    Time frame: Up to approximately 5 years

  6. Pharmacokinetics of sonesitatug vedotin (Cohort 1 and Cohort 2)

    Pharmacokinetic parameters of sonesitatug vedotin (peak plasma concentration (Cmax))

    Time frame: Up to approximately 5 years

  7. Pharmacokinetics of sonesitatug vedotin (Cohort 1 and Cohort 2)

    Pharmacokinetic parameters of sonesitatug vedotin (trough plasma concentration (Cmin))

    Time frame: Up to approximately 5 years

  8. Immunogenicity of sonesitatug vedotin (Cohort 1 and Cohort 2)

    Presence of ADAs for sonesitatug vedotin in serum (confirmatory results: positive or negative, titres).

    Time frame: Up to approximately 5 years

  9. Pharmacokinetics of rilvegostomig (Cohort 1)

    Pharmacokinetic parameters of rilvegostomig (peak plasma concentration (Cmax))

    Time frame: Up to approximately 5 years

  10. Pharmacokinetics of rilvegostomig (Cohort 1)

    Pharmacokinetic parameters of rilvegostomig (trough plasma concentration (Cmin))

    Time frame: Up to approximately 5 years

  11. Immunogenicity of rilvegostomig (Cohort 1)

    Presence of ADAs for rilvegostomig in serum (confirmatory results: positive or negative, titres).

    Time frame: Up to approximately 5 years

  12. Safety and tolerability (Cohort 1 and Cohort 2)

    Safety and tolerability as evaluated in terms of incidence of AEs and SAEs

    Time frame: Up to approximately 5 years

07

Study locations

158 of 314 sites recruiting
  • Research Site
    Birmingham, Alabama 35294-3300, United States
    Not yet recruiting
  • Research Site
    Mobile, Alabama 36604, United States
    Not yet recruiting
  • Research Site
    Anchorage, Alaska 99508, United States
    Not yet recruiting
  • Research Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Research Site
    Springdale, Arkansas 72762, United States
    Not yet recruiting
  • Research Site
    Duarte, California 91010, United States
    Not yet recruiting
  • Research Site
    Fountain Valley, California 92708, United States
    Recruiting
  • Research Site
    Fullerton, California 92835, United States
    Not yet recruiting
  • Research Site
    Irvine, California 92612, United States
    Recruiting
  • Research Site
    La Jolla, California 92093, United States
    Recruiting
  • Research Site
    Los Alamitos, California 90720, United States
    Not yet recruiting
  • Research Site
    Orange, California 92868, United States
    Recruiting
  • Research Site
    Walnut Creek, California 94598, United States
    Recruiting
  • Research Site
    Whittier, California 90602, United States
    Not yet recruiting
  • Research Site
    Denver, Colorado 80210, United States
    Not yet recruiting
  • Research Site
    Lone Tree, Colorado 80124, United States
    Recruiting
  • Research Site
    New Haven, Connecticut 06510, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Newark, Delaware 19713, United States
    Not yet recruiting
  • Research Site
    Washington D.C., District of Columbia 20007, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fort Myers, Florida 33901, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Jacksonville, Florida 32207, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Recruiting
  • Research Site
    Orlando, Florida 32806, United States
    Not yet recruiting
  • Research Site
    St. Petersburg, Florida 33705, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    West Palm Beach, Florida 33401, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Atlanta, Georgia 30309, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30342, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Macon, Georgia 31201, United States
    Recruiting
  • Research Site
    Newnan, Georgia 30265, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • Research Site
    Niles, Illinois 60714, United States
    Recruiting
  • Research Site
    Zion, Illinois 60099, United States
    Not yet recruiting
  • Research Site
    Indianapolis, Indiana 46260, United States
    Recruiting
  • Research Site
    Waukee, Iowa 50263, United States
    Not yet recruiting
  • Research Site
    Lexington, Kentucky 40536, United States
    Not yet recruiting
  • Research Site
    Louisville, Kentucky 40217, United States
    Not yet recruiting
  • Research Site
    Silver Spring, Maryland 20910, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    Burlington, Massachusetts 01803, United States
    Not yet recruiting
  • Research Site
    Worcester, Massachusetts 01655, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • Research Site
    Burnsville, Minnesota 55337, United States
    Recruiting
  • Research Site
    Duluth, Minnesota 55805, United States
    Not yet recruiting
  • Research Site
    Minneapolis, Minnesota 55455, United States
    Not yet recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    Kansas City, Missouri 64132, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Research Site
    Camden, New Jersey 08103, United States
    Not yet recruiting
  • Research Site
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • Research Site
    Hackensack, New Jersey 07601, United States
    Not yet recruiting
  • Research Site
    New Brunswick, New Jersey 08901, United States
    Not yet recruiting
  • Research Site
    Summit, New Jersey 07901, United States
    Recruiting
  • Research Site
    New York, New York 10029, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10032, United States
    Not yet recruiting
  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    The Bronx, New York 10461, United States
    Not yet recruiting
  • Research Site
    The Bronx, New York 10468, United States
    Recruiting
  • Research Site
    White Plains, New York 10601, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Research Site
    Wilmington, North Carolina 28403, United States
    Recruiting
  • Research Site
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Columbus, Ohio 43221, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97213, United States
    Recruiting
  • Research Site
    Portland, Oregon 97239, United States
    Not yet recruiting
  • Research Site
    Hershey, Pennsylvania 17033, United States
    Not yet recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15240, United States
    Not yet recruiting
  • Research Site
    Wilkes-Barre, Pennsylvania 18711, United States
    Recruiting
  • Research Site
    York, Pennsylvania 17403, United States
    Recruiting
  • Research Site
    Providence, Rhode Island 02903, United States
    Not yet recruiting
  • Research Site
    Charleston, South Carolina 29425, United States
    Not yet recruiting
  • Research Site
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • Research Site
    Yankton, South Dakota 57078, United States
    Recruiting
  • Research Site
    Memphis, Tennessee 38104, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site
    Dallas, Texas 75235, United States
    Not yet recruiting
  • Research Site
    Dallas, Texas 75246, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Not yet recruiting
  • Research Site
    Sherman, Texas 75090, United States
    Recruiting
  • Research Site
    Blacksburg, Virginia 24060, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Falls Church, Virginia 22042, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fort Belvoir, Virginia 22060, United States
    Not yet recruiting
  • Research Site
    Richmond, Virginia 23219, United States
    Recruiting
  • Research Site
    Edmonds, Washington 98026, United States
    Recruiting
  • Research Site
    Issaquah, Washington 98029, United States
    Recruiting
  • Research Site
    Olympia, Washington 98502, United States
    Not yet recruiting
  • Research Site
    Seattle, Washington 98104, United States
    Recruiting
  • Research Site
    Charleston, West Virginia 25304, United States
    Not yet recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
  • Research Site
    Darlinghurst, 2010, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Garran, 2605, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Heidelberg, 3084, Australia
    Recruiting
  • Research Site
    Murdoch, 6150, Australia
    Recruiting
  • Research Site
    Randwick, 2031, Australia
    Recruiting
  • Research Site
    Westmead, 2145, Australia
    Recruiting
  • Research Site
    Woolloongabba, 4102, Australia
    Not yet recruiting

Showing the first 100 of 314 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. 'Yes' indicates that AstraZeneca is accepting requests for IPD, but this does not mean that all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via the secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing the requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2029, 42 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's planned 42 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Feb 24, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Aug 16, 2029
CompletionEst.
Oct 27, 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed. 43 sites changed recruiting status (42 now recruiting, 1 now not yet recruiting)
Show 43 sites
  • Research Site · Fountain Valley, United StatesNot yet recruiting→Recruiting
  • Research Site · Irvine, United StatesNot yet recruiting→Recruiting
  • Research Site · La Jolla, United StatesNot yet recruiting→Recruiting
  • Research Site · Orange, United StatesNot yet recruiting→Recruiting
  • Research Site · Jacksonville, United StatesRecruiting→Not yet recruiting
  • Research Site · Atlanta, United StatesNot yet recruiting→Recruiting
  • Research Site · Macon, United StatesNot yet recruiting→Recruiting
  • Research Site · Indianapolis, United StatesNot yet recruiting→Recruiting
  • Research Site · Rochester, United StatesNot yet recruiting→Recruiting
  • Research Site · New York, United StatesNot yet recruiting→Recruiting
  • Research Site · The Bronx, United StatesNot yet recruiting→Recruiting
  • Research Site · Philadelphia, United StatesNot yet recruiting→Recruiting
  • Research Site · Wilkes-Barre, United StatesNot yet recruiting→Recruiting
  • Research Site · Richmond, United StatesNot yet recruiting→Recruiting
  • Research Site · Barrie, CanadaNot yet recruiting→Recruiting
  • Research Site · Harbin, ChinaNot yet recruiting→Recruiting
  • Research Site · Bordeaux, FranceNot yet recruiting→Recruiting
  • Research Site · Rennes, FranceNot yet recruiting→Recruiting
  • Research Site · Leipzig, GermanyNot yet recruiting→Recruiting
  • Research Site · München, GermanyNot yet recruiting→Recruiting
  • Research Site · Stuttgart, GermanyNot yet recruiting→Recruiting
  • Research Site · Ulm, GermanyNot yet recruiting→Recruiting
  • Research Site · Debrecen, HungaryNot yet recruiting→Recruiting
  • Research Site · Győr, HungaryNot yet recruiting→Recruiting
  • Research Site · Nyíregyháza, HungaryNot yet recruiting→Recruiting
  • Research Site · Pécs, HungaryNot yet recruiting→Recruiting
  • Research Site · Ahmedabad, IndiaNot yet recruiting→Recruiting
  • Research Site · Hyderabad, IndiaNot yet recruiting→Recruiting
  • Research Site · Mumbai, IndiaNot yet recruiting→Recruiting
  • Research Site · New Delhi, IndiaNot yet recruiting→Recruiting
  • …and 13 more on the registry record
Show 4 added (2 United States, 2 Malaysia)
  • Research Site · Whittier, United States
  • Research Site · Jacksonville, United States
  • Research Site · Kota Kinabalu, Malaysia
  • Research Site · Petaling Jaya, Malaysia
Show 1 removed
  • Research Site · New York, United States
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    4 sites added, 1 site removed. 43 sites changed recruiting status (42 now recruiting, 1 now not yet recruiting)
    Show 43 sites
    • Research Site · Fountain Valley, United StatesNot yet recruiting→Recruiting
    • Research Site · Irvine, United StatesNot yet recruiting→Recruiting
    • Research Site · La Jolla, United StatesNot yet recruiting→Recruiting
    • Research Site · Orange, United StatesNot yet recruiting→Recruiting
    • Research Site · Jacksonville, United StatesRecruiting→Not yet recruiting
    • Research Site · Atlanta, United StatesNot yet recruiting→Recruiting
    • Research Site · Macon, United StatesNot yet recruiting→Recruiting
    • Research Site · Indianapolis, United StatesNot yet recruiting→Recruiting
    • Research Site · Rochester, United StatesNot yet recruiting→Recruiting
    • Research Site · New York, United StatesNot yet recruiting→Recruiting
    • Research Site · The Bronx, United StatesNot yet recruiting→Recruiting
    • Research Site · Philadelphia, United StatesNot yet recruiting→Recruiting
    • Research Site · Wilkes-Barre, United StatesNot yet recruiting→Recruiting
    • Research Site · Richmond, United StatesNot yet recruiting→Recruiting
    • Research Site · Barrie, CanadaNot yet recruiting→Recruiting
    • Research Site · Harbin, ChinaNot yet recruiting→Recruiting
    • Research Site · Bordeaux, FranceNot yet recruiting→Recruiting
    • Research Site · Rennes, FranceNot yet recruiting→Recruiting
    • Research Site · Leipzig, GermanyNot yet recruiting→Recruiting
    • Research Site · München, GermanyNot yet recruiting→Recruiting
    • Research Site · Stuttgart, GermanyNot yet recruiting→Recruiting
    • Research Site · Ulm, GermanyNot yet recruiting→Recruiting
    • Research Site · Debrecen, HungaryNot yet recruiting→Recruiting
    • Research Site · Győr, HungaryNot yet recruiting→Recruiting
    • Research Site · Nyíregyháza, HungaryNot yet recruiting→Recruiting
    • Research Site · Pécs, HungaryNot yet recruiting→Recruiting
    • Research Site · Ahmedabad, IndiaNot yet recruiting→Recruiting
    • Research Site · Hyderabad, IndiaNot yet recruiting→Recruiting
    • Research Site · Mumbai, IndiaNot yet recruiting→Recruiting
    • Research Site · New Delhi, IndiaNot yet recruiting→Recruiting
    • …and 13 more on the registry record
    Show 4 added (2 United States, 2 Malaysia)
    • Research Site · Whittier, United States
    • Research Site · Jacksonville, United States
    • Research Site · Kota Kinabalu, Malaysia
    • Research Site · Petaling Jaya, Malaysia
    Show 1 removed
    • Research Site · New York, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07431281
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Feb 3, 2026
Primary completion
Aug 16, 2029 (estimated)
Completion
Oct 27, 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sonesitatug vedotin · Rilvegostomig

Start the discussion